Kliogest

Norethisterone acetate, the active ingredient in Kliogest, is a combined estrogen‑progestogen presented as an oral tablet for oral administration. Together with estradiol, it provides both estrogen and progestogen activity to replace declining endogenous hormones, helping to alleviate menopausal vasomotor symptoms and to prevent ovulation for contraception. It also contributes to the maintenance of bone mineral density, which is important in post‑menopausal women.

GNH USA supplies Kliogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity for global distribution.

Kliogest, a combined estrogen‑progestogen, is used in therapeutic areas that involve hormonal regulation. - Menopausal symptom relief: Reduces hot flashes, night sweats and improves quality of life in peri‑ and post‑menopausal women. - Osteoporosis prevention: Helps maintain bone mineral density and reduces risk of fractures in post‑menopausal patients. - Contraception: Suppresses ovulation and stabilizes the endometrium to provide reliable combined oral contraceptive protection.

Kliogest may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset. - Headache: transient tension‑type headaches. - Breast tenderness: swelling or discomfort. - Irregular vaginal bleeding: spotting or breakthrough bleeding.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Stroke: ischemic or hemorrhagic cerebrovascular events. - Severe allergic reaction: anaphylaxis or angioedema.

Before prescribing Kliogest, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiovascular risk: evaluate history of thrombosis, stroke, or myocardial infarction. - Screen for hormone‑dependent cancers: avoid use in active breast, endometrial or ovarian cancer. - Monitor liver function: contraindicated in severe hepatic impairment. - Counsel on smoking: advise against use in women over 35 who smoke. - Review concomitant medications: consider interactions with anticoagulants or enzyme inducers. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Kliogest can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce hormonal levels and contraceptive efficacy. - Anticoagulants (e.g., warfarin): increased risk of thrombotic events when combined with estrogen.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs (e.g., phenytoin, phenobarbital): may decrease hormone concentrations. - Antifungal agents (e.g., ketoconazole): may increase hormone levels, raising side‑effect risk. - Selective serotonin reuptake inhibitors (SSRIs): may exacerbate mood changes.